Literature DB >> 12578794

Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.

Joel A Schulman1, Chanping Liang, Lakshmana M Kooragayala, John King.   

Abstract

PURPOSE: To determine the incidence and type of posterior segment complications associated with the use of interferon alpha 2b and ribavirin in patients with chronic hepatitis C.
DESIGN: A prospective noncomparative case series. PARTICIPANTS: Forty-two patients (84 eyes).
METHODS: Patients with chronic hepatitis C were evaluated for ocular changes while being treated with interferon alpha 2b and ribavirin. Patients were followed with sequential ocular examinations for 4 to 20 months. MAIN OUTCOME MEASURES: Occurrence of posterior segment complications while on interferon and ribavirin therapy.
RESULTS: Twenty-seven patients developed retinopathy. The retinopathy consisted of single-to-multiple cotton-wool spots and retinal hemorrhage and was transient in all cases. An additional patient (age 46) presented with asymptomatic disc edema and hemorrhage. One other individual developed a symptomatic permanent monocular visual field defect. Therapy was discontinued in three patients because of severe posterior segment pathology.
CONCLUSIONS: Our study demonstrated that a high incidence of retinopathy is associated with the treatment of hepatitis C using interferon and ribavirin, but that this form of retinopathy is relatively benign. Regular ophthalmic monitoring should be performed in patients undergoing this treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578794     DOI: 10.1016/S0161-6420(02)01741-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

1.  [Anterior ischemic optic neuropathy and retinopathy during systemic interferon therapy].

Authors:  M Moerchen; A-K Rowton; K-H Emmerich
Journal:  Ophthalmologe       Date:  2007-08       Impact factor: 1.059

Review 2.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

3.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

4.  Ophthalmological side effects of interferon therapy of chronic hepatitis C.

Authors:  Eman Medhat; Gamal Esmat; Eman Hamza; Amr Abdel Aziz; Waleed Fouad Fathalah; Samar Kamal Darweesh; Zeinab Zakaria; Sameh Mostafa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

Review 5.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 6.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 7.  Uveitic macular edema.

Authors:  C Fardeau; E Champion; N Massamba; P LeHoang
Journal:  Eye (Lond)       Date:  2016-06-03       Impact factor: 3.775

8.  Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C.

Authors:  Hiten G Sheth; Michel Michaelides; Dilani Siriwardena
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

Review 9.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Ocular complications associated with systemic medications used in allergy/immunology practice.

Authors:  Avinash Gurbaxani; Clare L Fraser; Simon E Skalicky; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.